Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
S. Salloway,R. Sperling,21 Authors,H. Brashear
2014 · DOI: 10.1056/NEJMoa1304839
New England Journal of Medicine · 1,763 Citations
TLDR
Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers.